Sinofn Health
Sinofn Health
Science-Driven Nutraceutical Solutions | Bridging Global Innovation to EU Standards
Portugal represents a dynamic growth market within the European Union for nutraceuticals and special medical foods. As local consumer awareness regarding "Healthy Aging" (Envelhecimento Saudável) increases, the demand for scientifically backed OEM/ODM services has surged.
The synergy between Chinese manufacturing precision and EU quality compliance creates a unique competitive advantage for Portuguese brands. SINOFN provides full-cycle support, ensuring that products are not only manufactured to high standards but are also aligned with EFSA (European Food Safety Authority) regulations.
We understand that the Portugal market requires specific documentation, labeling accuracy, and batch traceability. Our "Local-First" approach involves adapting formulations to meet Mediterranean lifestyle preferences, including gluten-free, vegan-friendly, and natural sweetener profiles popular among Portuguese consumers.
Founded in 2012 with backing from the Chinese Academy of Sciences, SINOFN is not just a factory—it is a research powerhouse. Our founder, Mrs. GuoHong Liu, transitioned from clinical work to specialized nutrition, creating a legacy of "Profit with Purpose."
Led by Dr. Tan Shengjie (Peking University Medical Doctor) and Dr. Zhang Ying (CAS Postdoc), our R&D team continuously explores cutting-edge market technologies, ensuring that our partners in Portugal stay ahead of global industry trends.
Yes. We operate with ISO22000, HACCP, and FSSC 22000 certifications. We work closely with our partners to ensure all formulation parameters meet the stringent requirements of EFSA and local Portuguese market health authorities.
Absolutely. We provide tiered service packages, from pilot-scale prototyping for new brands to large-scale industrial production for established enterprises.
Thanks to our dedicated R&D center and experienced team, we offer rapid prototyping. Once the formulation is approved, we ensure efficient transition from pilot run to mass production.
